<SEC-DOCUMENT>0001279569-17-000120.txt : 20170130
<SEC-HEADER>0001279569-17-000120.hdr.sgml : 20170130
<ACCEPTANCE-DATETIME>20170130091145
ACCESSION NUMBER:		0001279569-17-000120
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20170130
FILED AS OF DATE:		20170130
DATE AS OF CHANGE:		20170130

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ESSA Pharma Inc.
		CENTRAL INDEX KEY:			0001633932
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A1
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37410
		FILM NUMBER:		17555511

	BUSINESS ADDRESS:	
		STREET 1:		SUITE 720
		STREET 2:		999 WEST BROADWAY
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V5Z 1K5
		BUSINESS PHONE:		(778) 331-0962

	MAIL ADDRESS:	
		STREET 1:		SUITE 720
		STREET 2:		999 WEST BROADWAY
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V5Z 1K5
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>essa6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION
</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Washington, D.C. 20549 </B></P>

<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>FORM 6-K </B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>Report of Foreign Private Issuer
</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Pursuant to Rule 13a-16 or 15d-16
</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>of the Securities Exchange Act of
1934 </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>For the month of January 2017</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>Commission File Number 001-37410
</B></P>

<P STYLE="font: 24pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>ESSA Pharma Inc. </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Translation of registrant&rsquo;s
name into English) </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>Suite 720, 999 West Broadway,
Vancouver, British Columbia, Canada, V5Z 1K5 </B></P>

<P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Address of principal executive offices)
</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 24.5pt">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:</P>

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Form
20-F </FONT><FONT STYLE="font-family: Wingdings">x</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"> Form 40-F </FONT><FONT STYLE="font-family: Wingdings">&#168;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT></P>

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): </FONT><FONT STYLE="font-family: Wingdings">&#168;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT></P>

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): </FONT><FONT STYLE="font-family: Wingdings">&#168;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT></P>

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 4pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt"></P>

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBITS
INCLUDED AS PART OF THIS REPORT </B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 7%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 90%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font: bold 8pt/107% Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit(s)</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD NOWRAP STYLE="vertical-align: top; font: 10pt/107% Calibri, Helvetica, Sans-Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt/107% Calibri, Helvetica, Sans-Serif"><P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press
                                         Release Dated January 30, 2017: ESSA receives US$4.0 million grant payment from Cancer Prevention Research Institute of Texas</FONT></P>


</TD></TR>
</TABLE>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SIGNATURES </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 24.5pt">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 45%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 44%">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: bottom">
        <P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0 0 1pt; text-align: center; border-bottom: black 0.75pt solid"><FONT STYLE="font-size: 10pt"><B><I>E</I></B></FONT><B><I><FONT STYLE="font-size: 7.5pt">SSA</FONT><FONT STYLE="font-size: 10pt">
        P</FONT><FONT STYLE="font-size: 7.5pt">HARMA</FONT><FONT STYLE="font-size: 10pt"> I</FONT><FONT STYLE="font-size: 7.5pt">NC</FONT><FONT STYLE="font-size: 10pt">.</FONT></I></B></P></TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: bottom; font: 10pt/107% Calibri, Helvetica, Sans-Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant)</FONT></TD></TR>
<TR>
    <TD COLSPAN="3">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top; font: 10pt/107% Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
      January 30, 2017</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt/107% Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0 0 1pt; border-bottom: black 0.75pt solid"><FONT STYLE="font-size: 10pt">/</FONT><FONT STYLE="font-size: 7.5pt">S</FONT><FONT STYLE="font-size: 10pt">/
        D</FONT><FONT STYLE="font-size: 7.5pt">AVID</FONT><FONT STYLE="font-size: 10pt"> W</FONT><FONT STYLE="font-size: 7.5pt">OOD</FONT></P></TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Name:</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 1pt">Title:</P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">David Wood</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 1pt">Chief Financial Officer</P></TD></TR>
</TABLE>
<P STYLE="font: 11pt/107% Calibri, Helvetica, Sans-Serif; margin: 0 0 8pt">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex991.htm
<DESCRIPTION>NEWS RELEASE DATED JANUARY 30, 2017
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"><B>Exhibit 99.1</B></FONT></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: center; margin: 0"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0"></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 9.75pt 0"><IMG SRC="image_002.jpg" ALT="Photo_Asset_1" STYLE="height: 148px; width: 400px"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0"></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt"><B>ESSA receives US$4.0 million grant payment from Cancer
Prevention Research Institute of Texas</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">HOUSTON, TX, Jan. 30, 2017 /CNW/ - ESSA Pharma Inc. (TSX:
EPI; NASDAQ: EPIX) (&quot;ESSA&quot; or the &quot;Company&quot;) a pharmaceutical company, currently in the clinical development
stage, focused on the development of small molecule drugs for the treatment of prostate cancer announced today the receipt of
a US$4.0 million payment from the Cancer Prevention Research Institute of Texas (&quot;CPRIT&quot;).&nbsp; The payment is part
of a total non-dilutive grant of US$12.0 million, repayable out of potential product revenues, which was originally awarded in
February 29, 2014.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">The payment recognizes eligible expenditures made by ESSA
in conducting the Phase 1 dose escalation trial currently underway, and also costs incurred in preparation for the Phase 2 dose
expansion clinical study expected to begin later this year.&nbsp; The Company is eligible to receive a further US$1.4 million upon
satisfactory completion of financial and compliance filings with CPRIT.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">&quot;The financial support from CPRIT since 2014 has been
instrumental to ESSA in building a top-tier team in Houston to guide the clinical development of EPI-506,&quot; said Dr. David
R. Parkinson, ESSA President and Chief Executive Officer.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">The Company initiated the Phase 1/2 clinical trial of EPI-506
in late 2015 and continues to dose patients in the Phase 1 portion of the clinical trial at sites in the United States and Canada.&nbsp;
The clinical trial is designed to demonstrate the safety, tolerability, maximum tolerated-dose, pharmacokinetics and efficacy of
EPI-506 in the treatment of prostate cancer patients who have failed treatments using abiraterone or enzalutamide or both, the
current standard-of-care drugs in metastatic castrate-resistant prostate cancer (&quot;mCRPC&quot;).&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0"><B>About</B>&nbsp;<B>ESSA</B>&nbsp;<B>Pharma</B>&nbsp;<B>Inc.</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">ESSA is a clinical-stage pharmaceutical company focused on
developing novel and proprietary therapies for the treatment of castration resistant prostate cancer (&quot;CRPC&quot;) in patients
whose disease is progressing despite treatment with current therapies. ESSA believes that its product candidate, EPI-506, can significantly
expand the interval of time in which patients suffering from CRPC can benefit from hormone-based therapies. EPI-506 acts by disrupting
the androgen receptor (&quot;AR&quot;) signaling pathway, which is the primary pathway that drives prostate cancer growth. EPI-002,
the primary metabolite of EPI-506, prevents AR activation by binding selectively to the N-terminal domain (&quot;NTD&quot;) of
the AR. A functional NTD is essential for activation of the AR. Blocking the NTD prevents activation of the AR by all of the three
known mechanisms of activation. In pre-clinical studies, blocking the NTD has demonstrated the capability to overcome the known
AR-dependent mechanisms of CRPC. ESSA was founded in 2009.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0"><B>About Cancer Prevention Research Institute of Texas</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">To date, CPRIT has awarded $1.67 billion in grants to Texas
researchers, institutions and organizations. The agency began making awards in 2009 after Texas voters overwhelmingly approved
a 2007 constitutional amendment committing $3 billion to the fight against cancer. CPRIT provides funding through its academic
research, prevention, and product development research programs. Programs made possible with CPRIT funding have reached all 254
counties of the state, brought more than 113 distinguished researchers to Texas, advanced scientific and clinical knowledge, and
provided more than 3.22 million life-saving education, training, prevention and early detection services to Texans.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0"><B>About Prostate Cancer</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">Prostate cancer is the second-most commonly diagnosed cancer
among men and the fifth most common cause of male cancer death worldwide (Globocan, 2012). Adenocarcinoma of the prostate is dependent
on androgen for tumor progression and depleting or blocking androgen action has been a mainstay of hormonal treatment for over
six decades. Although tumors are often initially sensitive to medical or surgical therapies that decrease levels of testosterone,
disease progression despite castrate levels of testosterone generally represents a transition to the lethal variant of the disease
(mCRPC) and most patients ultimately succumb to the illness. The treatment of mCRPC patients has evolved rapidly over the past
five years; despite these advances, additional treatment options are needed to improve clinical outcomes in patients, particularly
those who fail existing treatments including abiraterone or enzalutamide, or those that have contraindications to receive those
drugs. Over time, patients with mCRPC generally experience continued disease progression, worsening pain, leading to substantial
morbidity and limited survival rates. In both in vitro and in vivo animal studies, ESSA's novel approach to blocking the androgen
pathway has been shown to be effective in blocking tumor growth when current therapies are no longer effective.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0"><B>Forward-Looking Statement Disclaimer</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0"><I>This release contains certain information which, as presented,
constitutes &quot;forward-looking information&quot; within the meaning of the Private Securities Litigation Reform Act of 1995
and/or applicable Canadian securities laws. Forward-looking information involves statements that relate to future events and often
addresses expected future business and financial performance, containing words such as &quot;anticipate&quot;, &quot;believe&quot;,
&quot;plan&quot;, &quot;estimate&quot;, &quot;expect&quot;, and &quot;intend&quot;, statements that an action or event &quot;may&quot;,
&quot;might&quot;, &quot;could&quot;, &quot;should&quot;, or &quot;will&quot; be taken or occur, or other similar expressions and
includes, but is not limited to, statements about the Company's upcoming Phase 1/2 clinical trial; expectations regarding the initiation
of the Phase 2 dose expansion study; receipt of additional CPRIT funds; and</I>&nbsp;<I>the implementation of the Company's business
model and strategic plans.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0"><I>Forward-looking statements and information are subject
to various known and unknown risks and uncertainties, many of which are beyond the ability of ESSA to control or predict, and which
may cause ESSA's actual results, performance or achievements to be materially different from those expressed or implied thereby.
Such statements reflect ESSA's current views with respect to future events, are subject to risks and uncertainties and are necessarily
based upon a number of estimates and assumptions that, while considered reasonable by ESSA as of the date of such statements, are
inherently subject to significant medical, scientific, business, economic, competitive, political and social uncertainties and
contingencies. In making forward looking statements, ESSA may make various material assumptions, including but not limited to (i)
obtaining positive results of clinical trials; (ii) obtaining regulatory approvals; and (iii) general business, market and economic
conditions.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0"><I>Forward-looking information is developed based on assumptions
about such risks, uncertainties and other factors set out herein and in ESSA's</I>&nbsp;<I>Annual Report on Form 20-F dated December
14, 2016 under the heading &quot;Risk Factors&quot;, a copy of which is available on ESSA's profile at the SEDAR website at www.sedar.com,
ESSA's profile on EDGAR at www.sec.gov, and as otherwise disclosed from time to time on ESSA's SEDAR profile. Forward-looking statements
are made based on management's beliefs, estimates and opinions on the date that statements are made and ESSA undertakes no obligation
to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change, except as may
be required by applicable Canadian and United States securities laws. Readers are cautioned against attributing undue certainty
to forward-looking statements.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">SOURCE ESSA Pharma Inc</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">To view this news release in HTML formatting, please use the
following URL: http://www.newswire.ca/en/releases/archive/January2017/30/c4681.html</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">%CIK: 0001633932</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><B>For further information:</B> David S. Wood, Chief Financial Officer,
Tel: (778) 331-0962</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">CO: ESSA Pharma Inc</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">CNW 08:15e 30-JAN-17</P>



<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  0" P,# @0# P,$! 0$!0D&!04%
M!0L(" 8)#0L-#0T+# P.$!01#@\3#PP,$A@2$Q46%Q<7#A$9&QD6&A06%Q;_
MVP!# 00$! 4%!0H&!@H6#PP/%A86%A86%A86%A86%A86%A86%A86%A86%A86
M%A86%A86%A86%A86%A86%A86%A86%A;_P  1" "4 9 # 1$  A$! Q$!_\0
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M.Z/6K C=;TW5K1AO:--Q5Z*E*>Y,UDJ4M:BMQ14M1WED]9/$GVQZ 4%G$ (
M0 @! " $ ( 0!-VP';WNQKRBIN("F:%(.S1)'#I%_HD>OSUGU1$8U5T+71[S
MR^Y+8-2T[G2W+/[%YR0D=W**@6XJQM9[1<Q*SLS9FGL\$.LJ4U4:PT<E"N1:
M8/:.2E]1X)X\8L6&X2FE5KKR7/D5[$<5:;I4'YOES*INN..NK==6IQQQ14M:
MU%2E$\R2>)/>8LBU;"N-YGY@! " $ ( 0 @#TK,HSUQ7?2J!+@ERJ3S,JG'[
MZPDGU D^J-=6HJ=.4WV+,V4J;J5(P7:\C9](2S,G),RDN@(98;2VVD<DI2,
M>P1Y])MMME_BE%9(QG6/4"A:<6<]<%<=.Z/,EI9O'2S;I'!M /7PR3R R3&^
MUM:ES44(?\.>ZNJ=O3<Y_P#2A.M.J-TZFU\SU=FRB4:63)TUE1#$J.X?K*[5
MGB>X<(N=I94K:.4%K[7VO]W%/NKRK<RSF]78NQ&%QUG(( 0 @! " $ ( MEX
M->W=RF7)=;K9R^\U3V%=R!TB_M6CV16L?J_%"FO,L>!4OAG4?D6DBO%A$ (
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M_P 0C]I>-X]VZ.J+Q86:M:*C_L]O[X%)O[MW-9R[%L_?$CZ.XXA " $ ( 0
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ME4AT+*%)00XDX."K/P1RCHN,9E7MY4G')OMS.>WP>-&O&HI9I=A8*(4FA "
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M]*E<U67O3=2F"ZM.<AL<DH3W)2 D>B+[0HQHTU3CL11:]65:HZDMK/'C::A
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M3ZHC,7J]':26_42>$TM.[B]VLOR.0BF%Q$ ( 0 @! " $ ( 0 @! " /#O\
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ME2R4CU)W1ZHL]"FJ5*,%V(K5>HZE64WVO,\B-IJ$ ( 0!.W@\9GH=>)EG/\
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MKR+77J*E2E-]BS-8SKCCKBG7E%3CBBMQ1ZU$Y)]I,>@I9:D4%O-YGY@?! "
M)FT4VAZKIK8;-L4RU*=-MMONON3#TVXA;JUJR20!@8&!Z (BKO"H7-7I)3:^
MA*6F*2MJ2IQ@F9;Y8US_ ")I'\\[_;'-U!2[[X(Z>OJO<7$>6-<_R)I'\\[_
M &PZ@I=]\$.OJO<7$>6-<_R)I'\\[_;#J"EWWP0Z^J]Q<1Y8US_(FD?SSO\
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5]=_U9E8  X1.$*<P @! " $ ?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
